Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Dendritic cell (DC) generation and manipulation technology for the development of a cancer vaccine and rheumatoid arthritis (RA) therapeutics. Based on DC manipulating technology, Creagene is developing DC-based cancer vaccines against renal cell car More
These hybrid antibody molecules can be engineered with a variety of small synthetic molecules, and the combination of immunogenic properties results in compounds with powerful target destruction or imaging capabilities. More
A microRNA gene expression profile in prostate cancers that correlates with androgen responsiveness More
Methods and assays which may be used to diagnose and follow the progression of cancers associated with c-Met expression More
Experiments in vitro demonstrate that these novel SMO inhibitors potentially suppress the growth of cancer cells and inhibit the expression of the HH/PTCH pathway genes. More
Multiple immortalized, malignant, human, adult prostate epithelial cell lines useful as models in epithelial cell oncogenesis studies and in the diagnosis and treatment of prostate cancer More
A vector to be used for transfection and purification of human soluble FcRn receptor More
This technology describes several antibodies, both polyclonal and monoclonal, to the prolactin receptor. More
Grape skin extract, or purified fractions thereof, inhibited metastatic growth in human prostate transformed cell lines More
Immunogenic TARP polypeptides that generate an immune response to breast or prostate cancer cells that express TARP More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2009 - 160 pages - $2,265
Mar 2011 - 5 pages - $500
May 2011 - 5 pages - $500
Mar 2011 - 34 pages - $5,700
May 2011 - 5 pages - $500
Mar 2011 - 120 pages - $3,500
Jan 2010 - $75
Nov 2010 - 1011 pages - $1,495
Nov 2010 - 26 pages - $125
Nov 2010 - 50 pages - $500
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Adenocarcinoma
- Benign prostatic hypertrophy
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us